Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Oncoimmunology Edris, B., Willingham, S., Weiskopf, K., Volkmer, A. K., Volkmer, J. P., Mühlenberg, T., Weissman, I. L., van de Rijn, M. 2013; 2 (6): e24452

Abstract

Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentially bypass imatinib resistance in preclinical models of GIST.

View details for DOI 10.4161/onci.24452

View details for PubMedID 23894705

View details for PubMedCentralID PMC3716740